よむ、つかう、まなぶ。
05 参考資料１－２ 13価肺炎球菌コンジュゲートワクチン（成人用）ファクトシート (25 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36630.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第22回 12／1）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Immunization Practices (ACIP). MMWR 63:822-5, 2014.
45．Smith
KJ,
Wateska
AR,
Nowalk
MP,
Raymund
M,
Nuorti
JP,
Zimmerman
RK.
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate
vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 307:804-812,2012.
46．Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering
13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal
polysaccharide vaccine to adults with immunocompromising conditions. Vaccine.
31:6011-6021,2013.
47．Stoecker C. Incremental Cost-Effectiveness of Modifying PPSV and PCV Recommendations
for Adults Age 50 and Over. June 2014. Available at: http://www.cdc.gov/vaccines/
acip/meetings/downloads/slides-2014-06/pcv13-02-stoecker.pdf
48．Ochoa-Gondar
O,
Vila-Corcoles
A,
Rodriguez-Blanco
T,
Gomez-Bertomeu
F,
Figuerola-Massana E, Raga-Luria X, et al. Effectiveness of the 23-valent
pneumococcal polysaccharide vaccine against community-aqcuired pneumonia in the
general population ≥ 60 years: 3years of follow-up in the CAPAMIS study. Clin Infect
Dis. 58:909-917,2014
49．Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al.
Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving
survival in nursing home residents: double blind, randomized and placebo controlled
trial. BMJ 340: c1004, 2010.
50．Kobayashi M. Intervals between PCV13 and PPSV23 Vaccines: evidences supporting
currently
recommended
intervals
and
proposed
changes.
Available
at:
http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/pneumo-02-ko
bayashi.pdf
25
45．Smith
KJ,
Wateska
AR,
Nowalk
MP,
Raymund
M,
Nuorti
JP,
Zimmerman
RK.
Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate
vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 307:804-812,2012.
46．Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering
13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal
polysaccharide vaccine to adults with immunocompromising conditions. Vaccine.
31:6011-6021,2013.
47．Stoecker C. Incremental Cost-Effectiveness of Modifying PPSV and PCV Recommendations
for Adults Age 50 and Over. June 2014. Available at: http://www.cdc.gov/vaccines/
acip/meetings/downloads/slides-2014-06/pcv13-02-stoecker.pdf
48．Ochoa-Gondar
O,
Vila-Corcoles
A,
Rodriguez-Blanco
T,
Gomez-Bertomeu
F,
Figuerola-Massana E, Raga-Luria X, et al. Effectiveness of the 23-valent
pneumococcal polysaccharide vaccine against community-aqcuired pneumonia in the
general population ≥ 60 years: 3years of follow-up in the CAPAMIS study. Clin Infect
Dis. 58:909-917,2014
49．Maruyama T, Taguchi O, Niederman MS, Morser J, Kobayashi H, Kobayashi T, et al.
Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving
survival in nursing home residents: double blind, randomized and placebo controlled
trial. BMJ 340: c1004, 2010.
50．Kobayashi M. Intervals between PCV13 and PPSV23 Vaccines: evidences supporting
currently
recommended
intervals
and
proposed
changes.
Available
at:
http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/pneumo-02-ko
bayashi.pdf
25